| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL6 |
| Clinical data | |
| Other names | ALD518, BMS-945429 |
| Routes of administration | infusion |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6426H9972N1724O2032S42 |
| Molar mass | 145239.02 g·mol−1 |
Clazakizumab (formerlyALD518 andBMS-945429), aninvestigational drug, is anaglycosylated, humanized rabbitmonoclonal antibody againstinterleukin-6.[1] Clazakizumab was developed byBristol Myers Squib andAlder Biopharmaceuticals. A preliminary randomized, double-blind,placebo-controlled,phase 2 dose-ranging study of clazakizumab inpsoriatic arthritis patients, funded by the manufacturer, suggested that clazakizumab may be an effective treatment option for musculoskeletal aspects ofpsoriatic arthritis; however, the antibody lacked adose-response effect.[2]
